Amdocs Limited (NASDAQ:DOX – Get Free Report) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 2,810,000 shares, a growth of 5.2% from the August 31st total of 2,670,000 shares. Based on an average trading volume of 653,400 shares, the days-to-cover ratio is currently 4.3 days. Currently, 2.5% of the shares of the stock are short sold.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in DOX. Norwood Financial Corp acquired a new stake in shares of Amdocs during the first quarter worth approximately $33,000. Central Pacific Bank Trust Division acquired a new position in Amdocs in the first quarter valued at approximately $53,000. Riverview Trust Co bought a new position in shares of Amdocs during the first quarter valued at approximately $55,000. Quarry LP lifted its holdings in shares of Amdocs by 168.9% in the 4th quarter. Quarry LP now owns 656 shares of the technology company’s stock worth $58,000 after purchasing an additional 412 shares during the last quarter. Finally, American National Bank acquired a new position in Amdocs during the 2nd quarter valued at approximately $76,000. 92.02% of the stock is currently owned by hedge funds and other institutional investors.
Amdocs Trading Up 0.5 %
Amdocs stock traded up $0.41 during trading on Tuesday, hitting $87.89. The company’s stock had a trading volume of 249,666 shares, compared to its average volume of 694,462. The stock’s fifty day moving average is $85.32 and its 200 day moving average is $83.71. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.24 and a current ratio of 1.24. Amdocs has a 1-year low of $74.41 and a 1-year high of $94.04. The stock has a market capitalization of $10.33 billion, a price-to-earnings ratio of 19.60, a P/E/G ratio of 1.54 and a beta of 0.74.
Amdocs Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.479 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.18%. Amdocs’s dividend payout ratio is currently 42.92%.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of Amdocs from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 13th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $102.50.
Check Out Our Latest Stock Report on Amdocs
Amdocs Company Profile
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Read More
- Five stocks we like better than Amdocs
- 3 Small Caps With Big Return Potential
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Financial Services Stocks Investing
- 2 Energy Stocks Fueling the AI Datacenter Boom
- The How and Why of Investing in Gold Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.